Sangrix restates 2025 loss per share to $59.47
Sangrix restated its December 2025 interim results for material classification and presentation errors, without changing total assets, liabilities or consolidated net loss.
Rhea-AI Filing Summary
SANGRIX INC. (BTOG) is restating its unaudited interim financial statements for the six months ended December 31, 2025 to correct material accounting errors. The changes address the classification of certain Class A Ordinary Shares with redemption rights, the presentation of interest on convertible debentures measured under the fair value option, and the measurement of deemed dividends related to warrants.
Total assets of $12.9 million and total liabilities of $14.7 million as of December 31, 2025 remain unchanged, as does the consolidated net loss of $8.6 million. The restatement reclassifies $4.2 million of Class A shares to mezzanine equity and reduces the deemed dividend on warrants from $9.7 million to $7.7 million, improving net loss attributable to Sangrix and adjusting basic and diluted loss per share from $(66.65) to $(59.47) on a restated weighted average of 275,813 shares.
Positive
- None.
Negative
- Material restatement: The company concluded prior December 31, 2025 interim financials contained material errors in share classification, interest presentation, and warrant-related deemed dividends, requiring a restatement.
- Shareholders’ deficit: As of December 31, 2025 (as restated), total shareholders’ (deficit) including noncontrolling interests was $(6.0 million), with liabilities of $14.7 million exceeding assets of $12.9 million.
Filing Explained
This Form 6-K/A amends SANGRIX’s August 6, 2026 interim filing: it furnishes a completed restatement of the
Key Figures
Total assets: $12.9 million
Total liabilities: $14.7 million
Total (deficit) equity: $(6.0 million)
+5 more
8 metrics
Total assets
$12.9 million
As of December 31, 2025 (as restated)
Total liabilities
$14.7 million
As of December 31, 2025 (as restated)
Total (deficit) equity
$(6.0 million)
Including noncontrolling interests, as of December 31, 2025 (as restated)
Consolidated net loss
$8.6 million
Six months ended December 31, 2025 (unchanged by restatement)
Deemed dividend on warrants (as restated)
$7.7 million
Down-round feature of warrants, six months ended December 31, 2025
Loss per share, basic and diluted (as restated)
$(59.47)
Six months ended December 31, 2025, after restatement
Weighted average ordinary shares
275,813 shares
Basic and diluted for six months ended December 31, 2025, split-adjusted
Class A shares subject to redemption
$4.2 million
Mezzanine equity for 66,668 Class A Ordinary Shares as of December 31, 2025
Key Terms
mezzanine equity, convertible debentures, fair value option, deemed dividend, +1 more
5 terms
mezzanine equity financial
"reclassification of certain Class A Ordinary Shares with redemption rights to mezzanine equity"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
convertible debentures financial
"presentation of interest expense associated with the convertible debentures measured under the fair value option"
Convertible debentures are loans a company issues that pay interest like a bond but can be swapped later for the company’s shares at a set price. For investors they act like a safety-net plus a shortcut: you get regular interest payments while retaining the option to join ownership if the share price rises, which offers upside potential but can dilute existing shareholders if conversion occurs.
fair value option financial
"convertible debentures measured under the fair value option"
An accounting election that lets a company measure eligible financial assets and liabilities at their current market price, recording gains and losses in the income statement as those prices move. For investors it matters because choosing the fair value option makes reported profits and asset values respond immediately to market swings—like revaluing a house to today’s sale price—so it can increase earnings volatility while giving a more up‑to‑date view of value.
deemed dividend financial
"measurement of deemed dividends attributable to outstanding warrants"
A deemed dividend is a tax and accounting rule that treats certain transactions as if the company paid a dividend to shareholders even when no actual cash distribution was made. Examples include forgiveness of shareholder debt, transfers of assets at below-market value, or some related-party transactions; treating them as dividends can change reported retained earnings and create tax liabilities. Investors care because deemed dividends can alter a company’s reported equity, affect future cash availability, and create tax consequences for shareholders, similar to realizing value from the company without a formal cash payout.
down round feature financial
"deemed dividend attributable to down round feature of warrants"
A down round feature is a clause in investment agreements that kicks in when a company raises money at a lower valuation than a prior round, automatically changing terms to compensate earlier investors. Think of it like a price-protection clause: if later shares sell for less, earlier investors get adjustments (such as extra shares or a reset of their conversion price) to make up the difference. It matters to investors because it shifts who owns how much of the company, increases dilution for founders and some shareholders, and signals how future returns and control may change after a weak financing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did SANGRIX INC. (BTOG) change in its December 2025 interim financials?
Sangrix restated its December 31, 2025 interim balance sheet and statement of operations to correct the classification of certain redeemable Class A shares, the presentation of interest on convertible debentures under the fair value option, and the measurement of deemed dividends from warrants.
Did the Sangrix (BTOG) restatement change total assets, liabilities, or consolidated net loss?
No. Total assets of $12.9 million, total liabilities of $14.7 million, and consolidated net loss of $8.6 million for the six months ended December 31, 2025 remained unchanged; the adjustments affected equity classification, net loss attributable to Sangrix, and loss per share.
What is Sangrix’s (BTOG) financial position as of December 31, 2025 after restatement?
As of December 31, 2025, Sangrix reported $12.9 million in total assets, $14.7 million in total liabilities, and total (deficit) equity of $(6.0 million), including noncontrolling interests, reflecting a shareholders’ deficit position.
How did the deemed dividend on Sangrix (BTOG) warrants change in the restatement?
The deemed dividend attributable to the down-round feature of outstanding warrants for the six months ended December 31, 2025 was reduced from $9.7 million to $7.7 million. This affected net loss attributable to Sangrix and loss per share but not consolidated net loss or total shareholders’ equity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
